77
Participants
Start Date
March 31, 2022
Primary Completion Date
August 16, 2024
Study Completion Date
August 16, 2024
BMS-986406
Specified dose on specified days
Nivolumab
Specified dose on specified days
Carboplatin
Specified dose on specified days
Pemetrexed
Specified dose on specified days
Paclitaxel
Specified dose on specified days
Local Institution - 0018, Jette
Local Institution - 0012, Brussels
Local Institution - 0023, Rosario
Local Institution - 0015, Edegem
Local Institution - 0024, Seoul
Local Institution - 0027, Seoul
Local Institution - 0032, Córdoba
Local Institution - 0025, Seoul
Local Institution - 0029, Viedma
Local Institution - 0026, Seongnam-si
Local Institution - 0006, Richmond
Local Institution - 0014, Madrid
Local Institution - 0009, Madrid
Local Institution - 0016, Madrid
Carolina BioOncology Institute, PLLC, Huntersville
Local Institution - 0008, Málaga
Local Institution - 0033, Pamplona
Local Institution - 0021, Birmingham
Sanford Cancer Center, Sioux Falls
Mary Crowley Cancer Research - Medical City Hospital, Dallas
The Angeles Clinic and Research Institute, A Cedars-Sinai Affiliate, Los Angeles
UCLA Health, Los Angeles
University California San Diego Moores Cancer Center, La Jolla
Local Institution - 0031, Kashiwa-shi
Local Institution - 0001, Hackensack
Local Institution - 0028, Buenos Aires
Local Institution - 0030, Barcelona
Local Institution - 0017, Barcelona
Institut Catala dOncologia ICO - Hospital Duran i Reynals Location, Barcelona
Lead Sponsor
Bristol-Myers Squibb
INDUSTRY